Bank of America Corp DE Makes New Investment in Maze Therapeutics, Inc. $MAZE

Key Points

• Bank of America initiated a position in Maze Therapeutics, purchasing 321,227 shares worth approximately $9.6 million, or about 0.58% of the company. Several other major institutions, including BlackRock, Alphabet, and ARCH Venture Management, also established stakes during the second quarter.
• Analyst sentiment is broadly positive, with Maze receiving an overall “Buy” rating and an average price target of $63.40. Targets range from $48 to $110, although Wall Street Zen downgraded the stock to “Sell.”
• Maze shares opened at $26.05, well below their 12-month high of $53.65. The clinical-stage biotech reported a quarterly loss of $0.76 per share, while insiders have sold about 191,459 shares worth $5.3 million over the past three months.

Bank of America Corp DE bought a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 321,227 shares of the company's stock, valued at approximately $9,585,000. Bank of America Corp DE owned approximately 0.58% of Maze Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. TRV GP IV LLC bought a new position in Maze Therapeutics during the 2nd quarter valued at approximately $133,502,907. ARCH Venture Management LLC purchased a new stake in shares of Maze Therapeutics during the second quarter valued at $122,983,582. BlackRock Inc. purchased a new stake in shares of Maze Therapeutics during the 2nd quarter valued at about $104,525,000. Jupiter Topco LLC bought a new stake in shares of Maze Therapeutics in the second quarter worth approximately $101,764,000. Finally, Alphabet Inc. purchased a new position in shares of Maze Therapeutics in the 2nd quarter worth $41,435,000.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on MAZE. Wall Street Zen downgraded Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Wedbush restated an "outperform" rating and issued a $48.00 price target on shares of Maze Therapeutics in a research report on Wednesday. TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. HC Wainwright reiterated a "buy" rating and set a $110.00 price objective on shares of Maze Therapeutics in a research note on Thursday. Finally, Citigroup started coverage on shares of Maze Therapeutics in a research report on Wednesday. They set a "buy" rating and a $50.00 price objective on the stock. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $63.40.

Maze Therapeutics Price Performance

Shares of Maze Therapeutics stock opened at $26.05 on Friday. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The firm has a market cap of $1.45 billion, a PE ratio of -10.34 and a beta of 2.17. Maze Therapeutics, Inc. has a 12 month low of $21.95 and a 12 month high of $53.65. The stock has a 50 day moving average of $27.12 and a 200 day moving average of $29.02.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76). On average, research analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Insider Buying and Selling

In other Maze Therapeutics news, insider Atul Dandekar sold 3,243 shares of Maze Therapeutics stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $84,350.43. Following the completion of the transaction, the insider directly owned 32,316 shares of the company's stock, valued at $840,539.16. The trade was a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Harold Bernstein sold 9,705 shares of the firm's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $26.22, for a total transaction of $254,465.10. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 191,459 shares of company stock valued at $5,263,539 in the last three months. Corporate insiders own 5.30% of the company's stock.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Citigroup issued bullish coverage. A correction clarified that Citi initiated Maze Therapeutics with a “Buy” rating and a $50 price target, implying substantial upside from recent levels. Citi subsequently upgraded the stock to “Strong Buy.” Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target
• Positive Sentiment: Additional analysts also see significant upside. BTIG initiated coverage with a “Buy” rating and a $50 target, while HC Wainwright reaffirmed its “Buy” rating and maintained a $110 target—more than four times the recent share price. BTIG Initiates Maze Therapeutics at Buy With $50 Price Target HC Wainwright Reaffirms Buy Rating
• Positive Sentiment: Wedbush rated the company “Outperform.” The additional constructive view reinforces the broader analyst optimism surrounding Maze’s prospects. Maze Therapeutics Earns Outperform Rating from Wedbush
• Neutral Sentiment: Reported short interest was zero shares. The September 24 report listed no shares sold short and a 0.0-day short-interest ratio. This could reduce evidence of bearish positioning, although the figure may reflect a reporting or data issue given the accompanying reference to a large increase in short interest. Maze Therapeutics Shares Moved, So What Is Driving Attention Now?

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze's lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.